

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Cresemba

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	Thoma.
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicab	le):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following qu	n for this patient that may support estions and sign.	approval. Please answer the
Q1. Which formulation of Cresemba is requested?		
☐ Oral capsules	☐ IV solution	
Q2. Is the patient a NEW start to therapy?		
☐ Yes	☐ No (please provide start	date)
Q3. Specify the prescriber's specialty.		
☐ Infectious Disease	Other (please specify)	
Q4. What diagnosis is this drug being prescribed for?		
☐ Invasive aspergillosis		
☐ Mucormycosis		
☐ Other (Please Specify)		
Q5. If for invasive aspergillosis, does the patient have fail contraindication to voriconazole?	re of an adequate trial of, clinica	ally significant intolerance, or
☐ Yes	□No	
Q6. If for mucormycosis, does the patient have failure of a	n adequate trial of, clinically sign	ificant intolerance, or



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Cresemba

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
contraindication to amphotericin B?	
☐ Yes	□No
Q7. Were the causative organisms isolated and identified (including histopathology)?	through fungal culture and other relevant laboratory studies
☐ Yes	□No
Q8. Does the patient have any of the following? Please sell Familial short QT syndrome Concurrent use of drugs that are strong inducers of wort) Concurrent use of drugs that are strong inhibitors of None of the above	CYP3A4 (e.g. phenytoin, carbamazepine, rifampin, St. John's
Q9. Does the patient have culture and sensitivity showing	susceptibility to Cresemba?
☐ Yes	□No
Q10. If not a new start, does the patient show need for conselect all that apply. Radiographic abnormalities have not stabilized Signs of active infection are still present Persistent immune defects present Other (please specify)	ntinuation of therapy through any of the following? Please
Q11. Who is the ENTITY that will be submitting the CLAIM Pharmacy Individual prescriber Provider or specialty group Facility Other (please specify)	for the DRUG and seeking reimbursement?
Q12. Provide name and NPI of the billing entity	
Q13. Will the claim for the drug be submitted as a MEDICA submitting a MEDICAL claim for drug reimbursement, answ	, , , , , , , , , , , , , , , , , , ,



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Cresemba

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

-	Prescriber Name:
Patient Name:	Supervising Physician:
☐ Medical	Pharmacy
Q14. Additional Comments	
Prescriber Signature	Date
□ Expedited/Urgent - By checking this box and s	signing above, I certify that applying the standard review timeframe may
seriously jeopardize the life or health of the enrol	ilee of the emolice's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document